Analyst Kostas Biliouris from BMO Capital maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report) and keeping the price ...

Volanesorsen, an antisense drug discovered by Ionis and co-developed by Ionis and its subsidiary Akcea Therapeutics is under review in the US and EU for patients with familial chylomicronemia ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $67.12, a high estimate of ...

It is playing catch-up with a rival Lp(a) targeting antisense drug from Novartis and development partner Akcea, called pelacarsen, which is already in a phase 3 trial called HORIZON with major ...

Disclosures The efgartigimod trial was sponsored by argenx and Zai Lab. Allen reported relationships with Akcea Therapeutics, Alexion, Alnylam, Annexon Biosciences, argenx, CSL Behring ...

MD, PhD, Founder, Chairman and Chief Executive Officer of Ionis Pharmaceuticals Akcea Therapeutics, 22 Boston Wharf Rd, 9th Fl, Boston, Massachusetts 02210, United States. It is a well-known fact ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Even though mortality and hospitalisation rates have improved, the quality of life for those living with hypertrophic cardiomyopathy (HCM) can be compromised with limiting symptoms such as exertional ...

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company"), today reported financial results for the first quarter ended March 31, 2024.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally.